SNTA has spent over 1 Billion dollars as a company and has some value. Unless they bring a drug to market soon they are toast. They have a 12% chance of doing so. As for my position i was out last Friday. Might consider joining the long wagon again if they find a partner. For now they are in limbo.
Absolutely, that is why SNTA is worth 300M. Their compound vault. The downside is $2.75 or a buyout ( hopefully for shareholders not a fire sale ). Up side is $25 in 2 or 3 years.
By Robert Weisman Boston Globe
Drug makers can expect to spend more than $2.5 billion during more than a decade before winning approval to sell a new prescription medicine, according to an estimate released Tuesday by the Tufts Center for the Study of Drug Development.
The center’s projected cost of $2.558 billion dwarfs the $802 million figure in its last major study, done in 2003 — the equivalent of $1.04 billion in 2013 dollars. That number has been widely cited at industry forums as evidence of the financial hurdles drug makers face.
Development costs have more than doubled over the past decade partly because scientists are tackling more complex diseases, resulting in more failures of experimental therapies, according to the center, which is affiliated with Tufts University.
Critics, however, said the new estimate ignores the role of public incentives and could be used by companies to justify higher prices.
The new estimate “is a very high number,” said Kenneth I. Kaitin, director of the Tufts center, a research group funded by corporations, foundations, and nongovernmental organizations. “I don’t think that anybody in the industry or at the Food and Drug Administration wouldn’t say drug development costs have gone up at a much greater rate than inflation and a much greater rate than we’ve seen in the past.”
Among other findings, the center also released data on Tuesday showing that only 11.8 percent of drug compounds entering clinical testing are eventually approved. Companies seek to recoup their investments not only in approved drugs but also in those that fail.
I am disappointed that she has not reached out to me. I am back home and live about 5 miles away from her and could easily caddy for her. It would be nice to have a long talk with her as we head down to Cape Cod where some courses stay open most of the winter. There is also a nice indoor range we could go to. Looking forward to her email. Can't wait for Q4 results.
A.W. sighting!! Seen at Ponkapaog Golf Course in Canton on the driving range. I know it is only down the street from her condo but it is a municipal course. Pinching pennies already. Signs of things to come? I thought she was supposed to be jet setting around the world setting up partnerships? Guess i couldn't wait till Q4. Happy trading..........
That's AOK. Appreciate your concern. I am not here for the long haul like many who bought long at over 4. Yesterday was a good day to double up and now at $3.255 all in. So someone needs to change the title of this thread. Will unload today when SNTA tests the $3 mark. I do agree this will be up close to $3.75 @ years end. oompa8 is correct that Q4 will tell how the golf queen steers this company.
Sentiment: Strong Sell
Will see where this goes after Q4 as agreed to. When i heard a new CEO talk about assembling a team to commercialize a product that is years away i go short. If i lose i lose. Now i am going for breakfast and then to the beach. Is that OK or should i go back on my word and sit on my perch squacking all day.
Yes it is a pump and dump stock. The symbol should be ATM. How many times has it slid more than 50% back under .95. The magic buy number. DJ is a clown milking this for all it is worth. Wasn't GE going to come in and buy it for 10 bucks a share when it finally turned a profit last year? This company is so wrong but all so wright if you know how to read a chart. Pump and dump forever.
I did. 3.11 was the all in. You can only put lip stick on a pig for so long. I was told come back after Q4. So lighten up Francis.
Yes they do. The ATM is now open for CPST. Back again @ .95. Been away from this pump and dump ATM since 1.50 in January. Hoping for another %50 return by March. Thanks for all those shorts that ran this down to my buy price once again. Been playing this stock for 5 years now and it never fails in its price range. So let the pumping begin. Just wish i had a lower buy order in.
DNDN was a one pony show. So is SNTA.
By Peg Brickley And Jeffrey Ng
Dendreon Corporation filed for Chapter 11 bankruptcy protection Monday after coming to terms with senior lenders on a restructuring that could mean a reorganization or a sale of its cancer drug operation.
In a news release, the Seattle company said the bankruptcy filing will allow continued delivery of its Provenge prostate cancer treatment. In a filing with the U.S. Bankruptcy Court in Wilmington, Del., Dendreon general counsel Robert Crotty said the company raised money based on expectations the drug would bring in billions in revenue, but found the drug was slower to catch on than expected.
Holders of 84% of a $620 million issue of convertible senior notes have signed a restructuring support agreement that calls for their debt to be converted to equity in a reorganized company. The support agreement is the result of talks with, among others, Deerfield Management Company, L.P., the largest holder of the debt issue, court papers say.
While it pursues a Chapter 11 turnaround, Dendreon will launch a court-supervised sale process, looking for a buyer that will continue producing the drug. Potential bidders will have to provide value of at least $275 million, Dendreon said. Companies in bankruptcy often file with a reorganization strategy in mind, but test the market by putting their assets up for auction. Court papers say efforts to sell Dendreon privately near the end of 2013 produced no bidders.
Dendreon filed for protection with $100 million in cash or cash equivalents, and won't need bankruptcy financing, according to the release.
As of the period ending Sept. 30, 2014, Dendreon had $340 million in assets and $660.7 million in liabilities on a book value basis. When hopes for Provenge were running high, Dendreon had 1,500 employees. Cost-containment efforts have reduced the workforce to 698 people, court papers say.
When Provenge won approval from the Food and Drug Administration in 2010, it was touted as ushering in a new era of treatments to marshal the immune system against cancer. But it never really gained traction in the market.
Its $93,000 price for a treatment that improved median survival by just over four months was one reason. Management missteps in understanding the market, including the fact that doctors had to pay for the complex treatment up front amid initial uncertainty over insurance reimbursement was another.
Then came competition. Johnson & Johnson's Zytiga was approved for advanced prostate cancer in 2011 followed by Xtandi from Medivation Inc. of San Francisco and Astellas Pharma Inc. of Japan.
Both were pills that were easy to prescribe, required no upfront investment for doctors and were backed by clinical trial data doctors were more comfortable with. In the face of these rivals, Provenge's market share was under 5%, according to one recent analyst report.
Ron Winslow contributed to this article.
Still a strong buy Johny Boy? If you like losers go to SNTA. This company is a mirror image.
So i am off a little. Was not on DNDN and SNTA is so like it. I have 20 more years to wait around if i do not get cancer and die 1st. There will never be a cure for cancer. Only snake oil that delays a slow painful death. Anyone in an advanced stage will die so these studies are useless. SNTA by way of DNDN by 2017.
Sentiment: Strong Sell
Time to short this again. Was going to sit out and troll the Capstone board but 3.08 will be a good start at a new short position. Happy hunting.
Sentiment: Strong Sell